Osteoblastic Bone Lesions Developing During Treatment With Erlotinib Indicate Major Response in Patients With Non-Small Cell Lung Cancer: A Brief Report
Journal of Thoracic Oncology - United States
doi 10.1097/jto.0b013e3181d3e47e
Full Text
Open PDFAbstract
Available in full text
Date
April 1, 2010
Authors
Publisher
Elsevier BV